Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.47 |
| ▸ | LTA4H | P09960 | 7/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084205 | 1.00 | HRH4 (0.47) | HRH4LTA4HBCHEPRKCICDK1 | |
| SCHEMBL14084203 | 0.97 | HRH4 (0.48) | HRH4LTA4HBCHECHRNB2CHRNA4 | |
| SCHEMBL14084202 | 0.97 | HRH4 (0.48) | HRH4LTA4HBCHECHRNB2CHRNA4 | |
| SCHEMBL14084248 | 0.93 | HRH4 (0.50) | HRH4BCHECDK1CCNB1CCNA2 | |
| SCHEMBL14084164 | 0.80 | HRH4 (0.50) | HRH4BCHEPRKCI | |
| SCHEMBL14084165 | 0.78 | HRH4 (0.48) | HRH4BCHE | |
| SCHEMBL14084163 | 0.76 | HRH4 (0.51) | HRH4BCHEPRKCI | |
| SCHEMBL14084226 | 0.76 | HRH4 (0.51) | HRH4BCHEPRKCI | |
| SCHEMBL13650585 | 0.76 | HRH4 (0.50) | HRH4LTA4HPRKCI | |
| SCHEMBL13650584 | 0.76 | HRH4 (0.50) | HRH4LTA4HPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | HRH4 3013/4885LTA4H 2158/4885BCHE 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.